AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Gurufocus

Published November 13, 2026 · Updated November 14, 2026

GH Research (GHRS) Q3 Earnings Beat Expectations; Market Focuses - GuruFocus

Read the full story at Gurufocus

psychedelic therapies underscores its strategic growth ambitions in a rapidly evolving biotech niche. The announcement of a strong cash balance of.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech